Ocugen’s Modifier Gene Therapy Doubles Down on Two Fronts This Month — Science First, Investors Next

Ocugen shares drop 19% in past month, but RSI near 25 signals oversold; May presentations at Retina World Congress and Stifel forum spotlight OCU400 Phase 3 and OCU410 data.

The stock has taken a beating over the past month, shedding nearly 19%, but Ocugen is banking on May’s twin billing to refocus attention on what really matters: a pipeline that is closing in on regulatory milestones. Shares ended Wednesday at €1.27 and have since drifted to €1.24, with a relative strength index of roughly 25 — a reading that technically screams oversold. On the year, however, the stock has more than doubled.

The first appearance lands on May 14 at the Retina World Congress in Fort Lauderdale, a gathering that draws more than 1,000 retinal specialists, healthcare providers and industry officials from the U.S. and over 50 countries. Ocugen will present its modifier gene therapy platform during the session on inherited and rare retinal diseases, moderated by prominent retina experts Kourous A. Rezaei and Rishi P. Singh. For a small biotech, the venue offers a rare chance to build credibility with the physicians who will ultimately influence trial enrollment, patient access and clinical acceptance down the road.

At the center of that scientific narrative sits OCU400, a gene therapy candidate targeting retinitis pigmentosa. The pivotal Phase 3 liMeliGhT study is fully enrolled with 140 participants — described by management as the first and largest registration-directed gene therapy trial to cover a broad patient population in this indication. The program spans more than 25 distinct genetic mutations. Ocugen plans to kick off a rolling biologics license application (BLA) in the third quarter of 2026 and expects to complete the submission by the second quarter of 2027. Manufacturing timelines are also firming up: process validation for OCU400 is on track for the second quarter of 2026, a critical step since commercial success hinges as much on scalable production as on clinical efficacy.

Alongside OCU400, the company is advancing OCU410 for geographic atrophy. Recent Phase 2 data showed that the optimal dose reduced lesion growth by 31% after one year. That result is part of a broader strategy that distinguishes Ocugen from traditional gene therapies. Instead of repairing a single mutation, the company’s modifier approach targets entire gene networks, aiming to restore cellular balance. The platform-agnostic design could substantially widen the addressable patient pool for diseases like retinitis pigmentosa and beyond.

The science is only one half of the equation. Eleven days after the Fort Lauderdale conference, Ocugen takes its case to the investment community on May 26 at Stifel’s virtual Ophthalmology Forum. A recording of the presentation will be available for 30 days afterward. The management team has been actively raising its profile among potential partners, having recently appeared at industry gatherings in Singapore and at the Cell & Gene Meeting on the Mediterranean. The goal is to inject the modifier gene therapy narrative into ongoing dialogues with the capital markets and larger pharmaceutical players.

Ocugen’s financial runway gives it time to execute those conversations. A recent private placement of convertible notes raised $115 million, part of which went toward retiring existing debt. The company now expects to hold approximately $112 million in cash, cash equivalents and restricted cash — enough to fund operations into 2028. If the remaining Janus Henderson warrants are exercised, an additional $15 million in gross proceeds could push that total to $127.1 million. That buffer is vital because late-stage gene therapy trials are expensive, and Ocugen still has multiple BLA submissions ahead.

With the Retina World Congress this week and Stifel’s forum later this month, the company is threading together scientific validation and investor outreach at a moment when the stock’s technical weakness suggests the market is waiting for something concrete. The next big catalyst will be the planned start of the rolling BLA for OCU400 in the third quarter of 2026, but the immediate question is whether the platform’s visibility this May can begin to restore confidence in a story that, for now, looks oversold.